MedTrace Logo

Intradermal Influenza Vaccine Study in Elders

NCT00504231 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 257

Last updated 2012-07-13

Study results available
· View outcomes & findings →

Summary

This randomized trial compared the immunogenicity of 60% dose intradermal (ID) influenza vaccination to standard intramuscular (IM) vaccination of full-dose or 60% dose vaccine. Pre- and postvaccination measurements in the hemagglutination inhibition antibody (HAI) titer were compared. Participants who received reduced-dose vaccine were revaccinated with full-dose IM vaccine.

Conditions

Interventions

BIOLOGICAL

Fluzone Influenza Vaccine (2007-2008)

Manufactured by Sanofi Pasteur

Sponsors & Collaborators

  • VA Puget Sound Health Care System

    collaborator FED

  • Seattle Institute for Biomedical and Clinical Research

    collaborator OTHER

  • PATH

    lead OTHER

Principal Investigators

  • Ru-Chien Chi, MD · VAPSHCS

  • Kathy Neuzil, MD · PATH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-01-31
Completion
2008-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504231 on ClinicalTrials.gov